Cargando…
S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY
BACKGROUND: Glutamatergic abnormalities in schizophrenia and bipolar disorder gave been identified using proton magnetic resonance spectroscopy (1H-MRS). Although schizophrenia and bipolar disorder are both known to involve extensive brain networks, most MRS studies have been done using single-voxel...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234728/ http://dx.doi.org/10.1093/schbul/sbaa031.231 |
_version_ | 1783535831967858688 |
---|---|
author | Lenroot, Rhoshel Upston, Joel Mayer, Grace Jones, Thomas Maudsley, Andrew Gasparovic, Charles Tohen, Mauricio Bustillo, Juan |
author_facet | Lenroot, Rhoshel Upston, Joel Mayer, Grace Jones, Thomas Maudsley, Andrew Gasparovic, Charles Tohen, Mauricio Bustillo, Juan |
author_sort | Lenroot, Rhoshel |
collection | PubMed |
description | BACKGROUND: Glutamatergic abnormalities in schizophrenia and bipolar disorder gave been identified using proton magnetic resonance spectroscopy (1H-MRS). Although schizophrenia and bipolar disorder are both known to involve extensive brain networks, most MRS studies have been done using single-voxel techniques. In this study we used whole brain 1H-MRS to examine glutamine-plus-glutamate (Glx) in early schizophrenia and bipolar disorder to examine metabolic abnormalities associated with affective and non-affective psychosis and with exposure to antipsychotic medication. METHODS: Three dimensional 1H-MRS was acquired in young schizophrenia (SCZ, N=36, 24 M, 22.8±3.9 years, 19 antipsychotic-naïve and 17 antipsychotic-treated), bipolar (N=13, 5 antipsychotic-naïve and 8 antipsychotic-treated), schizoaffective-bipolar type (N= 3, 2 antipsychotic-naïve and 1 antipsychotic-treated) subjects, and healthy controls (HC, N=29, 17M, 23±4.4yrs). Glx, N-acetylaspartate, choline, myo-inositol and creatine group contrasts from all individual voxels that met spectral quality were analyzed in common brain space (voxel-wise p-threshold=0.001), followed by cluster-corrected alpha value (p<0.05). Bipolar subjects (N=13) and schizoaffective-bipolar type (N=3) were combined (SBP) (N=16, 11M, 21.9±2.9yrs, 7 antipsychotic naïve and 9 antipsychotic-treated). RESULTS: SCZ subjects compared to HC had lower Glx in the left superior (STG) and middle temporal gyri (16 voxels, p=0.04) and increased creatine in two clusters involving left temporal, parietal and occipital regions (32, and 18 voxels, p=0.02 and 0.04, respectively). Antipsychotic-treated and naïve SCZ had similar Glx reductions (8/16 vs 10/16 voxels respectively, but p’s>0.05). However, creatine was higher in antipsychotic-treated vs HC’s in a larger left hemisphere cluster (100 voxels, p=0.01). Also in treated SCZ, choline was increased in left middle frontal gyrus (18 voxels, p=0.04). Finally, in antipsychotic-naive SCZ, NAA was reduced in right frontal gyri (19 voxels, p=0.05) and myo-inositol was reduced in the left cerebellum (34 voxels, p=0.02). SBP subjects had no significant differences from HC in any area of the brain for any of the metabolites at a voxel-wise p-threshold of 0.001. A cluster of reduced Glx was found at in the right cuneus and precuneus (276 voxels, p=0.05) using a less stringent voxel-wise p-threshold of p< 0.05. DISCUSSION: Data-driven spectroscopic brain examination supports the presence of reductions in Glx in the left STG early in the course of schizophrenia; this was not seen in individuals with bipolar symptoms. A trend toward decreased Glx in the right cuneus and pre-cuneus in bipolar and schizoaffective patients is consistent with previous findings of abnormal function in this area. The left STG may be a critical target for postmortem and neuromodulation studies in schizophrenia studies. |
format | Online Article Text |
id | pubmed-7234728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72347282020-05-23 S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY Lenroot, Rhoshel Upston, Joel Mayer, Grace Jones, Thomas Maudsley, Andrew Gasparovic, Charles Tohen, Mauricio Bustillo, Juan Schizophr Bull Poster Session I BACKGROUND: Glutamatergic abnormalities in schizophrenia and bipolar disorder gave been identified using proton magnetic resonance spectroscopy (1H-MRS). Although schizophrenia and bipolar disorder are both known to involve extensive brain networks, most MRS studies have been done using single-voxel techniques. In this study we used whole brain 1H-MRS to examine glutamine-plus-glutamate (Glx) in early schizophrenia and bipolar disorder to examine metabolic abnormalities associated with affective and non-affective psychosis and with exposure to antipsychotic medication. METHODS: Three dimensional 1H-MRS was acquired in young schizophrenia (SCZ, N=36, 24 M, 22.8±3.9 years, 19 antipsychotic-naïve and 17 antipsychotic-treated), bipolar (N=13, 5 antipsychotic-naïve and 8 antipsychotic-treated), schizoaffective-bipolar type (N= 3, 2 antipsychotic-naïve and 1 antipsychotic-treated) subjects, and healthy controls (HC, N=29, 17M, 23±4.4yrs). Glx, N-acetylaspartate, choline, myo-inositol and creatine group contrasts from all individual voxels that met spectral quality were analyzed in common brain space (voxel-wise p-threshold=0.001), followed by cluster-corrected alpha value (p<0.05). Bipolar subjects (N=13) and schizoaffective-bipolar type (N=3) were combined (SBP) (N=16, 11M, 21.9±2.9yrs, 7 antipsychotic naïve and 9 antipsychotic-treated). RESULTS: SCZ subjects compared to HC had lower Glx in the left superior (STG) and middle temporal gyri (16 voxels, p=0.04) and increased creatine in two clusters involving left temporal, parietal and occipital regions (32, and 18 voxels, p=0.02 and 0.04, respectively). Antipsychotic-treated and naïve SCZ had similar Glx reductions (8/16 vs 10/16 voxels respectively, but p’s>0.05). However, creatine was higher in antipsychotic-treated vs HC’s in a larger left hemisphere cluster (100 voxels, p=0.01). Also in treated SCZ, choline was increased in left middle frontal gyrus (18 voxels, p=0.04). Finally, in antipsychotic-naive SCZ, NAA was reduced in right frontal gyri (19 voxels, p=0.05) and myo-inositol was reduced in the left cerebellum (34 voxels, p=0.02). SBP subjects had no significant differences from HC in any area of the brain for any of the metabolites at a voxel-wise p-threshold of 0.001. A cluster of reduced Glx was found at in the right cuneus and precuneus (276 voxels, p=0.05) using a less stringent voxel-wise p-threshold of p< 0.05. DISCUSSION: Data-driven spectroscopic brain examination supports the presence of reductions in Glx in the left STG early in the course of schizophrenia; this was not seen in individuals with bipolar symptoms. A trend toward decreased Glx in the right cuneus and pre-cuneus in bipolar and schizoaffective patients is consistent with previous findings of abnormal function in this area. The left STG may be a critical target for postmortem and neuromodulation studies in schizophrenia studies. Oxford University Press 2020-05 2020-05-18 /pmc/articles/PMC7234728/ http://dx.doi.org/10.1093/schbul/sbaa031.231 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Session I Lenroot, Rhoshel Upston, Joel Mayer, Grace Jones, Thomas Maudsley, Andrew Gasparovic, Charles Tohen, Mauricio Bustillo, Juan S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title | S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title_full | S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title_fullStr | S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title_full_unstemmed | S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title_short | S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY |
title_sort | s165. glutamatergic abnormalities in early schizophrenia and bipolar disorder measured using whole-brain spectroscopy |
topic | Poster Session I |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234728/ http://dx.doi.org/10.1093/schbul/sbaa031.231 |
work_keys_str_mv | AT lenrootrhoshel s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT upstonjoel s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT mayergrace s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT jonesthomas s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT maudsleyandrew s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT gasparoviccharles s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT tohenmauricio s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy AT bustillojuan s165glutamatergicabnormalitiesinearlyschizophreniaandbipolardisordermeasuredusingwholebrainspectroscopy |